Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Feb 12, 2018 in Breast cancer | 0 comments

In a nutshell

This study examined whether loratadine (Claritin) or naproxen (Aleve) is better at treating bone pain associated with G-CSF treatment for patients undergoing chemotherapy for early stage breast cancer. This study concluded that there was no significant difference between the incidence of bone pain reported by patients taking loratadinenaproxen or no prophylactic treatment, but loratadine is recommended for its potential benefit. 

Some background

Chemotherapy is often used in breast cancer treatment, but can cause low white blood cell counts. Granulocyte-stimulating colony factor (G-CSF) can be given with chemotherapy. G-CSF is a naturally occurring protein which stimulates the growth of white blood cells in bone marrow. Treatments such filgrastim are used to address the low white blood cell counts and act as G-CSF in the body. However, bone pain can occur as a side-effect from G-CSF use. 

Naproxen or loratadine can be used prophylactically (before the side-effect occurs).  Naproxen is a non-steroidal anti-inflammatory drug, which is also used as a painkiller. Loratadine is an anti-histamine, which can also be used for hayfever allergies. It is unclear whether loratadine or naproxen is better at treating bone pain.  

 

Methods & findings

This study evaluated 600 patients who had early stage breast cancer. The patients were divided into three groups and were randomized to receive loratadinenaproxen or no prophylactic treatment.

There was no significant difference between bone pain reported by any of the groups. The severity of bone pain, as reported by patients, was lower for patients who took naproxen or loratadine. Loratadine was associated with fewer side effects and discontinuations than naproxen.

The bottom line

 This study concluded that there was no significant difference between the incidence of bone pain reported by patients taking loratadinenaproxen or no prophylactic treatment, but loratadine is recommended for its potential benefit and low side effects. 

The fine print

Other studies have reported benefits with the use of naproxen or loratadine. 

What’s next?

Discuss starting any over-the-counter treatment with your doctor. 

Published By :

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Date :

Nov 16, 2017

Original Title :

NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim.

click here to get personalized updates